A year on from Nanoform’s IPO in June 2020, we have made trailblazing progress. In this video, we share how we’ve transformed to reach key milestones, from the launch of our biologics technology to the completion of our first-in-human trial of a nanoformed drug candidate.
We were pleased to host a session, “Overcoming Drug Development Challenges with Nanotechnology,” at the first ever CPhI Discover virtual event. Nanoform CCO Christian Jones, FRSC, Nanoform Science & Technology Team Leader Elisabetta Micelotta, and experts from Johnson Matthey and Quotient Sciences shared insights into the power of sparse-data AI in drug development and the collaborative studies investigating the performance of our CESS® technology. Watch it here to learn more about AI-guided nanoparticle engineering in Pharma, from early drug development to clinic.
Our CCO, Christian Jones, FRSC, joined the Bio Integrates panel discussion “Start with an end in mind” on Thursday, May 20th, 2021. The panel explored the importance of connecting with patients to make sure that products are designed around the patient’s needs.
Overcoming Drug Development Challenges with Nanotechnology: Piroxicam, a commercially available non-steroidal anti-inflammatory drug, was nanoformed as a model compound to demonstrate the potential benefits of our CESS(R) nanoforming technology for improving solubility, dissolution and in vivo absorption.
We were excited to showcase the results from our collaboration with Johnson Matthey in our webinar with The Nanomed Zone: “How CESS® technology stacks up against the competition: the smaller, the better!”. Watch the presentation to learn how CESS® nanoparticles of a model compound have been found to exhibit improved dissolution performance relative to all other industry standard approaches tested, including spray drying.
Our Director of Pharmaceutical Development, Satu Lakio, gave a presentation at the 12th Global DDF Summit (Drug Delivery & Formulation) covering “Unique Nanoforming Technology for Poorly Soluble APIs by Nanoform”.
Our Head of AI, Prof. Jukka Corander joined a panel discussion at BIO-Europe Spring 2021 on “Big data & AI: applications in the real world”. Watch the video to find out out how Sparse Data AI & specifically STARMAP® can transform healthcare.
We achieved a number of milestones in 2020, check out the highlights here!
In partnership with Quotient Sciences, the healthy volunteers have been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate.
Hosted by Ted Danson, this episode of Advancements aimed to enlighten the public on how Nanoform’s award-winning CESS® nanoparticle engineering technology can potentially double the number of drug candidates progressing into clinic, open up new drug delivery routes and improve the lives of patients worldwide.
Join a virtual tour of our Helsinki facility to meet our experts, get up close to our award-winning technology, and even participate in real-time questions and discussions.
Our CTO Niklas Sandler, and Pharmaceutical Development Manager Satu Lakio explain how our nanoparticle engineering technology is revolutionizing oral drug delivery by enhancing solubility and bioavailability.
Our CEO Edward Hæggström, CFO Albert Hæggström, and CCO Christian Jones present an overview of our nanoforming platform technology at Avanza Börsdag.
Our CCO, Christian Jones, joins Dr. Sophia Ononye-Onyia on the Amplifying Scientific Innovation podcast to discuss his outlook on the life science industry and Nanoform’s unique focus on nanotechnology innovation.
A record of the conference call held to discuss Nanoform’s initiation of the first human trial of a drug candidate nanoformed using our proprietary CESS® technology.
Nanoform scientists outline how our innovative CESS® technology can help overcome the obstacles many drug candidates face when trying to make it through clinical trials.
Our CTO, Niklas Sandler, and Pharmaceutical Development Manager, Satu Lakio, discuss the advantages of our nanoparticle engineering technology in oral drug development and delivery by boosting solubility and bioavailability.
Our CCO, Christian Jones, discusses the launch our US subsidiary and the extension our partnership with Orion Corporation with Business Trends Magazine.
Nanoform CEO Edward Haeggström and CFO Albert Haeggström discussed the benefits of our cutting-edge nanoforming technology for improving efficiency in Pharma and increasing the rate of drug approval for market with CHEManager.
In this brochure we share our story, explaining how our unique nanoforming services, including our game-changing CESS® technology, can provide solutions to drug development challenges in Pharma.
Our CCO, Christian Jones, shares his thoughts at the DDF Summit on how our award-winning CESS® technology can change the future of medicine.
Our CBO, Dr. Gonçalo Rebelo de Andrade, discusses with Chemicals Knowledge Hub magazine how our nanoforming technology can improve efficiency in the pharmaceutical industry by creating new avenues for drug delivery.
Our CCO, Christian Jones, shared his insights with The Medicine Maker into how our nanoforming technology can improve efficiency and create new opportunities for drug development.
Our CCO, Christian Jones, joins The Medicine Maker to discuss the challenges that the drug discovery and development market face today, and how our nanoforming technology can help solve these issues and drive pharmaceutical efficiency.
Our CTO, Niklas Sandler, examines the importance of technological innovation for treating age-related diseases in Chemistry World’s Future of Pharma digital supplement.
Our scientists discuss the advantages of applying a multidisciplinary approach to Pharma innovation in the Chemistry World - Voices in Chemistry digital supplement.
Our CTO, Niklas Sandler, discusses the growing demand for nanoformed drug particles and the advantages of our proprietary nanoforming technology offers with Cleanroom Technology Magazine.
Our Head of AI, Jukka Corrander, spoke to Technology Networks about our innovative use of sparse data AI with our proprietary STARMAP™ technology.
Our CBO, Gonçalo Rebelo de Andrade, discusses the advantages offered by our excipient-free nanoforming technology with BioPharm International.
Our CTO, Niklas Sandler, explains how our innovative use of nanoforming technology and sparse-data AI is being used to enhance drug molecules in the European Pharmaceutical Manufacturer.
Our CTO, Niklas Sandler, and Head of AI, Jukka Corander, were interviewed by Contract Pharma to discuss the application of AI for enhanced drug particle engineering. At the Bio-Europe Spring meeting, our CCO, Christian Jones, discusses how we use physics to enhance drug discovery and development for our partners in the pharmaceutical industry.